Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
5 studies found for:    ETV6
Show Display Options
Rank Status Study
1 Unknown  Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia (CEL);   Myeloproliferative Disorders
Intervention: Drug: STI571
2 Recruiting Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors
Conditions: Neoplasms;   Central Nervous System Neoplasms
Intervention: Drug: LOXO-101 (larotrectinib)
3 Recruiting Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: Larotrectinib
4 Recruiting Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Conditions: Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Carcinoma, Ductal, Breast;   Melanoma;   Solid Tumors;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma
Intervention: Drug: LOXO-101
5 Recruiting Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Conditions: Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Lymphoma
Interventions: Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Pegaspargase;   Drug: Erwinase®;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Blinatumomab;   Drug: Ruxolitinib;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Clofarabine;   Drug: Vorinostat;   Drug: Idarubicin

Study has passed its completion date and status has not been verified in more than two years.